Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

September 2024

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai L,

Jiang C,

Zhang G,

Fang H,

Wang J,

Li Y,

Xu H,

Xiao R,

Ding Y,

Huang K,

Zhang C,

Zhang L,

Chen B,

Duan X,

Pan W,

Han G,

Chen R,

Liu L,

Zhang S,

Tao J,

Pang X,

Yu J,

Wang H,

Zhao Y,

Li C,

Kang X,

Qin L,

Zhu X,

Su J,

Li S,

Yang C,

Feng W,

Lei T,

Jiang S,

Fang R,

Lin M,

Lu Q,

Xu C,

Wang W,

Zhang J

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.

Keywords:

January 2014

Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implication for SYK inhibitors in autoimmune disease therapy

Arthritis Research and Therapy 2013 15:R146

Liao C,

Hsu J,

Kim Y et al

Spleen tyrosine kinase (SYK) has already been described as a potential therapeutic target for the treatment of autoimmune diseases. Previously the SYK inhibitor fostamatinib was in clinical development for the treatment of rheumatoid arthritis, but has since been suspended. However, investigation into SYK inhibition continues with RO2091, a novel ATP-competitive inhibitor of SYK with reasonable selectivity, potency and oral bioavailability which has been shown to suppress various innate and adap...